Search
Results: 40
SORL1 mutations in early- and late-onset Alzheimer disease.
Michael L Cuccaro, Regina M Carney, Yalun Zhang, Christopher Bohm, Brian W Kunkle, Badri N Vardarajan, Patrice L Whitehead, Holly N Cukier, Richard Mayeux, Peter St George-Hyslop, Margaret A Pericak-Vance
Feb 07, 2019
OBJECTIVE: To characterize the clinical and molecular effect of mutations in the sortilin-related receptor (SORL1) gene. METHODS: We performed whole-exome sequencing in early-onset Alzheimer disease (EOAD) and late-onset...
1109 Neurosciences Biomedical Basic Science Human Genome Alzheimer's Disease Clinical Research Dementia Brain Disorders Neurodegenerative aging Genetics Acquired Cognitive Impairment Neurosciences Alzheimer's Disease including Alzheimer's Disease Related Dementias (AD/ADRD) Neurological 2.1 Biological and endogenous factors
Expression profiles for macrophage alternative activation genes in AD and in mouse models of AD.
Carol A Colton, Ryan T Mott, Hayley Sharpe, Qing Xu, William E Van Nostrand, Michael P Vitek
Aug 10, 2017
BACKGROUND: Microglia are associated with neuritic plaques in Alzheimer disease (AD) and serve as a primary component of the innate immune response in the brain. Neuritic plaques are fibrous deposits composed of the amyloid...
1109 Neurosciences 1107 Immunology Biomedical Basic Science aging Acquired Cognitive Impairment Neurosciences Dementia Genetics Alzheimer's Disease including Alzheimer's Disease Related Dementias (AD/ADRD) Alzheimer's Disease Brain Disorders Neurodegenerative Neurological 2.1 Biological and endogenous factors
Dietary composition modulates brain mass and solubilizable Abeta levels in a mouse model of aggressive Alzheimer's amyloid pathology.
Steve Pedrini, Carlos Thomas, Hannah Brautigam, James Schmeidler, Lap Ho, Paul Fraser, David Westaway, Peter St George Hyslop, Ralph N Martins, Joseph D Buxbaum, Giulio M Pasinetti, Dara L Dickstein, Patrick R Hof, Michelle E Ehrlich, Sam Gandy
Jun 16, 2011
1109 Neurosciences Biomedical Basic Science aging Neurosciences Dementia Neurodegenerative Alzheimer's Disease including Alzheimer's Disease Related Dementias (AD/ADRD) Alzheimer's Disease Brain Disorders Nutrition Acquired Cognitive Impairment Neurological 2.1 Biological and endogenous factors 1.1 Normal biological development and functioning
Effects of sedimentation, microgravity, hydrodynamic mixing and air-water interface on α-synuclein amyloid formation.
Jiangtao Zhou, Francesco S Ruggeri, Manuela R Zimmermann, Georg Meisl, Giovanni Longo, Sergey K Sekatskii, Tuomas PJ Knowles, Giovanni Dietler
Jul 28, 2021
The formation of amyloid fibrils is a characterizing feature of a range of protein misfolding diseases, including Parkinson's disease. The propensity of native proteins to form such amyloid fibril, both in vitro and in vivo, is...
The neuroanatomical and neurochemical basis of apathy and impulsivity in frontotemporal lobar degeneration.
Apathy and impulsivity are common and often coexistent consequences of frontotemporal lobar degeneration (FTLD). They increase patient morbidity and carer distress, but remain under-estimated and poorly treated. Recent...
Cognitive training for freezing of gait in Parkinson's disease
Courtney C Walton, Loren Mowszowski, Moran Gilat, Julie M Hall, Claire O'Callaghan, Alana J Muller, Matthew Georgiades, Jennifer YY Szeto, Kaylena A Ehgoetz Martens, James M Shine, Sharon L Naismith, Simon JG Lewis
Sep 05, 2018
The pathophysiological mechanism of freezing of gait (FoG) has been linked to executive dysfunction. Cognitive training (CT) is a non-pharmacological intervention which has been shown to improve executive functioning in...
1103 Clinical Sciences Clinical Clinical Medicine and Science aging Mind and Body Neurosciences Neurodegenerative Clinical Research Brain Disorders Parkinson's Disease Behavioral and Social Science Acquired Cognitive Impairment Mental Health Clinical Trials and Supportive Activities Neurological 6.6 Psychological and behavioural
Acute dosing of latrepirdine (Dimebon), a possible Alzheimer therapeutic, elevates extracellular amyloid-beta levels in vitro and in vivo.
John W Steele, Soong H Kim, John R Cirrito, Deborah K Verges, Jessica L Restivo, David Westaway, Paul Fraser, Peter St George Hyslop, Mary Sano, Ilya Bezprozvanny, Michelle E Ehrlich, David M Holtzman, Sam Gandy
Jun 16, 2011
Microglia become hypofunctional and release metalloproteases and tau seeds when phagocytosing live neurons with P301S tau aggregates.
Jack H Brelstaff, Matthew Mason, Taxiarchis Katsinelos, William A McEwan, Bernardino Ghetti, Aviva M Tolkovsky, Maria Grazia Spillantini
Nov 03, 2021
Neuroserpin and transthyretin are extracellular chaperones that preferentially inhibit amyloid formation.
Jennifer West, Sandeep Satapathy, Daniel R Whiten, Megan Kelly, Nicholas J Geraghty, Emma-Jayne Proctor, Pietro Sormanni, Michele Vendruscolo, Joel N Buxbaum, Marie Ranson, Mark R Wilson
Jan 28, 2022
Neuroserpin is a secreted protease inhibitor known to inhibit amyloid formation by the Alzheimer’s beta peptide (Aβ). To test whether this effect was constrained to Aβ, we used a range of in vitro assays to demonstrate that...
An antibody scanning method for the detection of α-synuclein oligomers in the serum of Parkinson's disease patients.
Klara Kulenkampff, Derya Emin, Roxine Staats, Yu P Zhang, Laila Sakhnini, Antonina Kouli, Oded Rimon, Evgeniia Lobanova, Caroline H Williams-Gray, Francesco A Aprile, Pietro Sormanni, David Klenerman, Michele Vendruscolo
Jan 22, 2023
Misfolded α-synuclein oligomers are closely implicated in the pathology of Parkinson's disease and related synucleinopathies. The elusive nature of these aberrant assemblies makes it challenging to develop quantitative methods...
Is Dementia Screening of Apparently Healthy Individuals Justified?
1117 Public Health and Health Services Clinical Public Health aging Acquired Cognitive Impairment Neurosciences Dementia Clinical Research Alzheimer's Disease including Alzheimer's Disease Related Dementias (AD/ADRD) Alzheimer's Disease Brain Disorders Health Services Prevention Neurodegenerative Neurological 4.2 Evaluation of markers and technologies 7.3 Management and decision making
Trauma and depressive symptomatology in middle-aged persons at high risk of dementia
Karen Ritchie, Isabelle Carrière, Sarah Gregory, Tam Watermeyer, Samuel Danso, Li Su, Craig W Ritchie, John T O'Brien
Sep 28, 2020
OBJECTIVE: Depression and trauma are associated with changes in brain regions implicated in Alzheimer's disease. The present study examined associations between childhood trauma, depression, adult cognitive functioning and risk...
Clinical Research Alzheimer's Disease including Alzheimer's Disease Related Dementias (AD/ADRD) Brain Disorders aging Alzheimer's Disease Mental Health Neurodegenerative Behavioral and Social Science Acquired Cognitive Impairment Neurosciences Depression Prevention Dementia Mental Health Neurological
A fluorescent molecular imaging probe with selectivity for soluble tau aggregated protein.
Yanyan Zhao, Ole Tietz, Wei-Li Kuan, Abdul K Haji-Dheere, Stephen Thompson, Benjamin Vallin, Elisabetta Ronchi, Gergely Tóth, David Klenerman, Franklin I Aigbirhio
Apr 22, 2020
ApoE4 lowers age at onset in patients with frontotemporal dementia and tauopathy independent of amyloid-β copathology.
Carolin Koriath, Tammaryn Lashley, William Taylor, Ronald Druyeh, Athanasios Dimitriadis, Nicola Denning, Julie Williams, Jason D Warren, Nick C Fox, Jonathan M Schott, James B Rowe, John Collinge, Jonathan D Rohrer, Simon Mead
May 30, 2019
INTRODUCTION: Apolipoprotein E (ApoE) is the most important genetic risk factor for Alzheimer's disease (AD), with ApoE4 thought to enhance and accelerate amyloid-β (Aβ) pathology. ApoE4 has recently been described to increase...
1109 Neurosciences Acquired Cognitive Impairment Dementia Neurosciences Alzheimer's Disease including Alzheimer's Disease Related Dementias (AD/ADRD) frontotemporal dementia (FTD) aging Brain Disorders Neurodegenerative Alzheimer's Disease Alzheimer's Disease Related Dementias (ADRD) Genetics Neurological 2.1 Biological and endogenous factors
Behavioural and psychological symptoms in the older population without dementia - Relationship with socio-demographics, health and cognition
Alzheimer's Disease Alzheimer's Disease including Alzheimer's Disease Related Dementias (AD/ADRD) Brain Disorders Mental Health Behavioral and Social Science Neurodegenerative Acquired Cognitive Impairment aging Dementia 2 Aetiology 2.3 Psychological social and economic factors Mental Health Neurological 3 Good Health and Well Being Aged Behavioral Symptoms Cognition Disorders Dementia Demography Female health status Humans Longitudinal Studies Male Neuropsychological Tests prevalence Psychotic Disorders United Kingdom
Genetic Evidence for Protective Effects of Angiotensin-Converting Enzyme Against Alzheimer Disease But Not Other Neurodegenerative Diseases in European Populations.
David K Ryan, Ville Karhunen, Bowen Su, Matthew Traylor, Tom G Richardson, Stephen Burgess, Ioanna Tzoulaki, Dipender Gill
Oct 01, 2022
BACKGROUND AND OBJECTIVES: Angiotensin-converting enzyme (ACE) inhibitors are a commonly prescribed class of medication used to treat heart failure, hypertension, and chronic kidney disease. However, previous observational...
In vivo neuroinflammation and cerebral small vessel disease in mild cognitive impairment and Alzheimer's disease.
Audrey Low, Elijah Mak, Maura Malpetti, Luca Passamonti, Nicolas Nicastro, James D Stefaniak, George Savulich, Leonidas Chouliaras, Li Su, James B Rowe, Hugh S Markus, John T O'Brien
Aug 07, 2020
INTRODUCTION: Associations between cerebral small vessel disease (SVD) and inflammation have been largely examined using peripheral blood markers of inflammation, with few studies measuring inflammation within the brain. We...
High-Depth PRNP Sequencing in Brains With Sporadic Creutzfeldt-Jakob Disease.
Alexander G Murley, Yu Nie, Zoe Golder, Michael John Keogh, Colin Smith, James W Ironside, Patrick F Chinnery
Feb 23, 2023
BACKGROUND AND OBJECTIVES: Sporadic Creutzfeldt-Jakob disease (sCJD) has established genetic risk factors, but, in contrast to genetic and acquired CJD, the initial trigger for misfolded prion aggregation and spread is not...
Alzheimer's Disease including Alzheimer's Disease Related Dementias (AD/ADRD) Alzheimer's Disease Prevention Neurosciences Brain Disorders Rare Diseases Dementia Transmissible Spongiform Encephalopathy (TSE) Acquired Cognitive Impairment Infectious Diseases Emerging Infectious Diseases Neurodegenerative aging Genetics Human Genome 2.1 Biological and endogenous factors 2 Aetiology Neurological
Ultra-rare mutations in SRCAP segregate in Caribbean Hispanic families with Alzheimer disease.
Badri N Vardarajan, Giuseppe Tosto, Roger Lefort, Lei Yu, David A Bennett, Philip L De Jager, Sandra Barral, Dolly Reyes-Dumeyer, Peter L Nagy, Joseph H Lee, Rong Cheng, Martin Medrano, Rafael Lantigua, Ekaterina Rogaeva, Peter St George-Hyslop, Richard Mayeux
Mar 22, 2018
OBJECTIVE: To identify rare coding variants segregating with late-onset Alzheimer disease (LOAD) in Caribbean Hispanic families. METHODS: Whole-exome sequencing (WES) was completed in 110 individuals from 31 Caribbean Hispanic...
Longitudinal trajectories of amyloid deposition, cortical thickness, and tau in Down syndrome
Elijah Mak, Anastasia Bickerton, Concepcion Padilla, Madeleine J Walpert, Tiina Annus, Liam R Wilson, Young T Hong, Tim D Fryer, Jonathan P Coles, Franklin I Aigbirhio, Bradley T Christian, Benjamin L Handen, William E Klunk, David K Menon, Peter J Nestor, Shahid H Zaman, Anthony J Holland
May 23, 2019
Alzheimer's Disease Down Syndrome Neurosciences Dementia Neurodegenerative Alzheimer's Disease including Alzheimer's Disease Related Dementias (AD/ADRD) Acquired Cognitive Impairment Biomedical Imaging aging Brain Disorders Intellectual and Developmental Disabilities (IDD) 2.1 Biological and endogenous factors 2 Aetiology Neurological
Relationships between the amyloid precursor protein and its various proteolytic fragments and neuronal systems
Alzheimer's disease
OBJECTIVE: Peripheral protein biomarkers of Alzheimer's disease (AD) may help identify novel treatment avenues by allowing early diagnosis, recruitment to clinical trials, and treatment initiation. The purpose of this review was...
1109 Neurosciences Biomedical Clinical Medicine and Science aging Neurosciences Dementia Neurodegenerative Alzheimer's Disease including Alzheimer's Disease Related Dementias (AD/ADRD) Alzheimer's Disease Brain Disorders Acquired Cognitive Impairment Neurological 4.1 Discovery and preclinical testing of markers and technologies
Multifunctional peptide-assembled micelles for simultaneously reducing amyloid-β and reactive oxygen species.
The excessive production and deposition of amyloid-β (Aβ) is one of the most important etiologies of Alzheimer's disease (AD). The interaction between Aβ and metal ions produces aberrant reactive oxygen species (ROS), which...
Vascular health, diabetes, APOE and dementia
David J Llewellyn, Iain A Lang, Fiona E Matthews, Brenda L Plassman, Mary Am Rogers, Lewis B Morgenstern, Gwenith G Fisher, Mohammed U Kabeto, Kenneth M Langa
Jun 14, 2011
1117 Public Health and Health Services Clinical Public Health aging Acquired Cognitive Impairment Neurosciences Cardiovascular Dementia Clinical Research Alzheimer's Disease including Alzheimer's Disease Related Dementias (AD/ADRD) Alzheimer's Disease Brain Disorders Diabetes stroke Neurodegenerative Neurological Cardiovascular stroke
Proteasome-targeted nanobodies alleviate pathology and functional decline in an α-synuclein-based Parkinson's disease model.
Diptaman Chatterjee, Mansi Bhatt, David Butler, Erwin De Genst, Christopher M Dobson, Anne Messer, Jeffrey H Kordower
Nov 21, 2018
Therapeutics designed to target α-synuclein (α-syn) aggregation may be critical in halting the progression of pathology in Parkinson's disease (PD) patients. Nanobodies are single-domain antibody fragments that bind with...
|
|< |
< |
1 |